EISAI-E2020-A001-315

Study Sponsor: Eisai

Study Title

A 24 Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Donepezil Hydrochloride (E2020) in Patients With Severe Alzheimer's Disease Followed by a 12 Week Open-Label Extension Period

Medicine or Vaccine (generic name)

donepezil

Sponsor Identification Number

E2020-A001-315

Trial Registry Identification Number(#'s)

NCT00096473

Medical Condition

Alzheimer's Disease

Phase

Phase 3

Link to study details on the Eisai Clinical Study Register

not available

Link to study details on ClinicalTrials.gov (if available)

https://clinicaltrials.gov/ct2/show/NCT00096473

Link to study details on EudraCT (if available)

not available

Datasets and Documents Available for this Study

Additional information about the data and documents available for this study

No restrictions.

Date Added to this Site

August 2019